An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
Clinical trial NCT05275023 · COMPLETED
Trial details
- NCT number
- NCT05275023
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-30
- Primary completion
- 2023-12-12
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.